STTR Phase I: Novel Inhaled Nitric Oxide Therapy For Pulmonary Treatments (COVID-19)

STTR 第一阶段：用于肺部治疗的新型吸入一氧化氮疗法（COVID-19）

• 批准号: 2040043
• 负责人: steven riesinger
• 金额: $ 25.6万
• 依托单位: MedChem Partners LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2040043&HistoricalAwards=false
• 关键词: STTR; Phase; Novel; Inhaled; Nitric

The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project relates to the unmet need for new and effective therapeutics that target the lung. This proposal outlines a novel treatment for the pulmonary manifestations of COVID-19; however, this technology will also find use in other acute pulmonary disorders, such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), emphysema, and cystic fibrosis. Currently the options for treatment of pulmonary disorders include supplemental oxygen, ventilators, or nitrous oxide (NO) gas, which is toxic and cumbersome to use. Current technology uses gaseous NO which is a toxic gas supplied in high pressure tanks and is present only when inhaling the gas. The proposed project will develop a long-lasting, inhaled NO delivery system to improve lung function of patients suffering from ARDS brought on by COVID-19 or other causes.This Small Business Technology Transfer Phase I project advances translation of a novel molecule which sequesters NO chemically as a stable solid and can be engineered to degrade at a controlled rate for in situ continuous release. This proposal develops NO donors with optimized performance and stability for pulmonary delivery. Tasks include: develop and test libraries of NO donor compounds for the ability and rate of NO release; evaluate and select compounds with good solubility characteristics to formulate for aerosolization/ nebulization; test candidates for improvement of lung function in animal models.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业技术转让（STTR）I期项目的更广泛影响/商业潜力与针对肺部的新的有效疗法的未满足需求有关。该提案概述了COVID-19肺部表现的新型治疗方法;然而，该技术也将用于其他急性肺部疾病，如急性呼吸窘迫综合征（ARDS），慢性阻塞性肺疾病（COPD），肺气肿和囊性纤维化。目前，用于治疗肺部疾病的选择包括补充氧气、呼吸机或一氧化二氮（NO）气体，其是有毒的并且使用麻烦。目前的技术使用气态NO，其是在高压罐中供应的有毒气体，并且仅在吸入气体时存在。该项目将开发一种长效的吸入式NO输送系统，以改善因COVID-19或其他原因导致的ARDS患者的肺功能。该小企业技术转让I期项目推进了一种新型分子的翻译，该分子以化学方式将NO隔离为稳定的固体，并可以以受控的速度降解，以原位持续释放。该提议开发了具有优化的性能和稳定性的NO供体用于肺部递送。 任务包括：开发和测试NO供体化合物库的NO释放能力和速率;评估和选择具有良好溶解特性的化合物以配制用于雾化/雾化;测试候选物以改善动物模型的肺功能。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估来支持。